Statement-I

Sl. No.	Name of the Formulation	Name of the bulk drugs on which formulation is based
1.	Neosporin	Polymixin-B Sulphate, Zinc Bacitracin, Neomycin Sulphate
2.	Actifed	Pseudoophdrine, Triprolidine Hcl.
3.	Saridon	1-Phenyl-2, 3-dimethyl-4-Isopropyl-5-Pyrazolon, Paracetamol 3, -3 diethyl-2, 4-dioxo-Tetrahydropyridine, 1, 3, 7, Trimethyl-2 6-dioxopurine
4.	Suganril	Oxyphenylbutazone
6.	Nebasulf	Neomycin Sulphate, Bacitracin
7.	Dilosyn	Methdilazine
8.	Flucort	Flyocinoone Acetonide
9.	Benadryl	Dephenhydramine Hcl.

Production of Rifampicin in the Organised sector units

3737. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to refer to the Unstarred Question 1554 given in the Rajya Sabha on the 8th August, 1988 and state:

(a) when did the organised sector units register under the delicensing scheme for the production of Rifampicin, what is the capacity registered, what was the phased manufacturing programme of each registered and from what stage of chemical name each unit is registered;

(b) what has been the annual production of each unit from the date of commencement of production and what is the import made during each year and the CIF price of such imports;

(c) whether it is a fact that Kraunkar Labs have been allowed import recently for export of formulations and if so, what is the quantity imported and at what price imports have been made; and

(d) whether any instance of overcharging of price of formulations based on this drug has come to the notice of his Ministry and if so, since when the overinvoicing is going on?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Since 1985, several units have registered under the delicensing scheme for the manufacture of Rifampicin. Total capacity registered as on 31-7-88 is 1434 MT. Under the PMP, Rifampicin can be produced from intermediate stage for a period of two years. Thereafter manufacture should be from basic stage.

(b) Production of Rifampicin is not monitored by this Ministry. Details of imports are published in the Monthly Statistics for Foreign Trade in India, Vol. II, Copies of which are available in Parliament Library.

(c) M/s. Krankar Labs. have been allowed to import 625 kgs. of Rifampicin powder for export of formulations. The details of this export have been sought from the company and they have informed that they shall intimate the same as soon as the whole supply is executed.

(d) No instance of charging the price higher than fixed by the Government under 1987 DPCO for Rifampicin formulations has come to the notice of the Government.

Representations from NPCC Ltd. Workers' Union, Calcutta

3738. SHRI SAMAR MUKHERJEE: Will the Minister of ENERGY be pleased to state:

(a) whether Government have received any representation dated 19th December, 1987 from the National Projects Construction Corporation Ltd. Workers' Union (C.I.T.U.) 119, Bipin Behari Ganguly Street, Calcutta-700012;

(b) if so, what are the details thereof;

(c) whether any action has been taken on the said representaton;

(d) if so, what are the details thereof; and

(e) if not, what are the reasons for the delay in taking action thereon?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRI KALPNATH RAI): (a) Yes, Sir.

(b) The representation contains complaint about deployment of one official posted at Durgapur Unit of the NPCC on outstation jobs instead of his own duties in office, and payment of TA|DA to him in addition to O.T.A. and compensatory leave and also about non-implementation of his transfer orders from Durgapur Unit to Bokaro Unit.

(c) and (d) The complaint was enquired into and it was found that the concerned individual was sent on tour for official work and payments of allowances were made to him as per Rules. Keeping in view the requirement of Durgapur Unit, he has been retained there.

(e) Does not arise.

Representations received by the Kelkar Committee

3739. SHRIMATI BIJOYA CHAKRAVARTY:
SHRI CHITTA BASU:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the term of Kelkar Committee has been extended upto 30th Sept. 1980 to rectify anomalies, mistakes and discrepancies in identification of drugs for category-II;

(b) whether it is a fact that some Members of Parliament have submitted representations directly to Chairman of the Committee on Category-II drugs pointing out anomalies and discrepancies in Categorisation;

(c) if so, the total number of representations received upto 20th August, 1988 by Chairman from the Members of Parliament along with names and details of anomalies and discrepancies pointed out therein;

(d) how many representations of MPs have been considered from September 1987 upto August 88 and what are the details of decisions taken against each; and

(e) what is the total number of representations yet to be considered by the committee and by when all will be considered, decision taken and by when supplementary report is expected?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) to (e) Details of representations received by the Kelkar Committee from Members of Parliament are given in the enclosed Statement (*See* below) The representations are being looked into by the Committee.